Attenuated microorganisms for the treatment of infection
The present invention pertains to a Salmonella microorganism having an attenuating mutation which disrupts the expression of a gene located within the Spi2 pathogenicity island, and an auxotrophic mutation. The microorganism therefore has a double mutation which helps prevent reactivity of the microorganism while maintaining the effectiveness of the microorganism to elicit an immune response. The present invention also pertains to vaccine compositions and methods for treating and preventing a Salmonella infection in a patient.
1. An isolated Salmonella microorganism having an attenuating mutation which disrupts the expression of an ssaJ apparatus gene located within the Spi2 pathogenicity island, and an auxotrophic mutation which disrupts the expression of an aroC gene.
2. The microorganism according to claim 1 , wherein the attenuating mutation is within an intergenic region between ssaK and ssaJ.
3. The microorganism according to claim 1 , wherein the microorganism further comprises a heterologous antigen or a therapeutic protein.
4. The microorganism according to claim 3 , wherein the antigen is a hepatitis A, B or C antigen.
5. The microorganism according to claim 1 , wherein the microorganism is Salmonella typhi Ty2.
6. A vaccine composition comprising a microorganism according to claim 1 , and an adjuvant and a physiologically acceptable diluent.
7. The vaccine composition according to claim 6 , comprising from about 10 7 to about 10 10 CFUs in a single dosage unit.
8. The vaccine composition according to claim 7 , comprising from about 10 8 to about 10 9 CFUs in a single dosage unit.
9. A method for treating or preventing a Salmonella infection, comprising administering to a patient a microorganism according to claim 1 .
10. The method according to claim 9 , for the treatment of typhoid.